The groundbreaking therapy of this peptide represents a major development in the management of type 2 diabetes. Distinct from existing therapies, tirzepatide affects two pathways – GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) – resulting in greater sugar regulation and anticipated